Sponsored symposium: Prolonged release chewable tablets: Why Formulation Matters in ADHD (Neuraxpharm)

Join this practical and interactive session for an insightful discussion on the first UK prolonged‑release chewable formulation, and its role in paediatric and adolescent ADHD management. Chaired by Dr Maite Ferrin, Consultant Child and Adolescent Psychiatrist, the session will explore real‑world considerations when introducing a novel formulation, including adherence challenges, patient and family preferences, and everyday clinical decision‑making.

The session will review formulation technologies and how prolonged‑release delivery may offer benefits beyond chewability alone. This will be followed by an interactive Q&A with Dr Michael Feld, who will share international clinical perspectives alongside direct, hands‑on experience from routine clinical practice using different ADHD formulations.

 NXUK/A/0526/02 May 2026

This event is made possible by sponsorship from organisations including pharmaceutical companies, med tech companies and service providers who have provided sponsorship towards this independent programme. They have had no editorial input or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the marked sponsored symposia. Sessions delivered with input from these organisations are marked as such on the programme and a list of all sponsors can be found on our sponsor page.